Estrogen-related receptor alpha based protac compounds and associated methods of use
US10071164B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 10, 2015 |
| Grant date | Sep 11, 2018 |
| Priority date | — |
| Expiry date | Aug 10, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.